GlassScriptPhysician profile
William J Mast
NPI 1659089811
$11,087.20
in general payments reported to CMS, 2019-2025
23 companies · $4,058 in 2025
The $4,058 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $596 · 2023: $1,924 · 2024: $4,510 · 2025: $4,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,886 · Consulting Fee: $1,168 · Education: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,885.66 |
| Consulting Fee | $1,168.00 |
| Education | $437.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,510.16 | 2022-2025 | |
| Leo Pharma INC. | $1,344.28 | 2023-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $1,234.97 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $1,123.16 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $913.75 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $711.05 | 2023-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $669.14 | 2023-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $591.44 | 2023-2025 | |
| Ucb, INC. | $569.60 | 2023-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $463.51 | 2022-2025 | Winlevi, Ilumya, Absorica Ld |
| Arcutis Biotherapeutics, INC. | $383.65 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $367.57 | 2022-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $259.32 | 2023-2024 | Cabtreo, Siliq, Duobrii |
| Galderma Laboratories, L.P. | $196.41 | 2024-2025 | Nemluvio |
| Amgen INC. | $180.08 | 2023-2024 | Otezla |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $150.25 | 2022-2025 | |
| Epi Health, LLC | $100.03 | 2022 | |
| Eli Lilly and Company | $99.00 | 2025 | |
| Organon LLC | $92.07 | 2025 | Vtama |
| Incyte Corporation | $67.30 | 2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.89 | 2024 | Spevigo |
| Almirall LLC | $19.04 | 2024 | Seysara |
| Mayne Pharma Commercial LLC | $15.53 | 2023-2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.